← Back to Search

Probiotics for Clostridium Difficile Infection Recurrence

N/A
Waitlist Available
Led By Matthew Sims, PhD
Research Sponsored by Novozymes A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This trial studies if taking probiotics after CDI treatment can lower risk of recurrence. Adults with 2 CDI episodes will be included.

Who is the study for?
Adults over 18 who've had at least two bouts of C. difficile infection and finished standard antibiotic treatment within the past 5 days can join. They must be able to consent, provide samples, and not be pregnant or breastfeeding. Those on certain diets or treatments that affect the study, with immune issues, active diarrhea, or chronic intestinal diseases cannot participate.Check my eligibility
What is being tested?
The trial is testing Bacillus velezensis DSM 33864—a probiotic—against a placebo to see if it lowers the chance of another C. difficile infection after standard treatment in adults with a history of recurrent infections.See study design
What are the potential side effects?
Potential side effects are not explicitly listed for this probiotic intervention but may include digestive discomfort such as gas or bloating. Placebos typically have no side effects but can cause reactions based on an individual's belief about taking an active substance.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
C. difficile colonization
C.difficile colonization
Presence and levels of C. difficile toxin in fecal samples
+2 more
Other outcome measures
Body Weight Changes
Fatty Acids, Volatile
Changes in blood C-reactive protein (CRP) levels
+11 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Bacillus velezensis DSM 33864Experimental Treatment1 Intervention
This arm will receive a single strain probiotic capsule containing Bacillus velezensis DSM 33864. The probiotic will be taken orally, once a day, for 8 weeks.
Group II: Placebo control groupPlacebo Group1 Intervention
A placebo capsule containing microcrystalline cellulose will be taken orally, once a day, for 8 weeks.

Find a Location

Who is running the clinical trial?

Evidilya S.r.l.UNKNOWN
4 Previous Clinical Trials
584 Total Patients Enrolled
Estimates OYUNKNOWN
Novozymes A/SLead Sponsor
12 Previous Clinical Trials
840 Total Patients Enrolled

Media Library

Bacillus velezensis DSM 33864 Clinical Trial Eligibility Overview. Trial Name: NCT05606159 — N/A
Clostridium Difficile Infection Research Study Groups: Placebo control group, Bacillus velezensis DSM 33864
Clostridium Difficile Infection Clinical Trial 2023: Bacillus velezensis DSM 33864 Highlights & Side Effects. Trial Name: NCT05606159 — N/A
Bacillus velezensis DSM 33864 2023 Treatment Timeline for Medical Study. Trial Name: NCT05606159 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is registration currently open for participation in this research project?

"Unfortunately, according to clinicaltrials.gov this particular medical trial is not currently recruiting patients. The study was first posted on the 1st of January 2023 and recently modified on October 31, 2022. However, 1793 other trials are actively seeking volunteers at present time."

Answered by AI
~52 spots leftby Nov 2024